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Abstract 30 
Aim: To investigate the clinical long-term outcomes 13 years following guided tissue 31 
regeneration (GTR) in deep intrabony defects with and without additional application of 32 
autogenous platelet concentrate (APC). 33 
Methods: In 25 patients, two deep contra-lateral intrabony defects were treated according to 34 
GTR using ß-TCP and bio-resorbable membranes. In test defects, APC was applied 35 
additionally. After 13 years, clinical healing results were assessed and compared to results at 36 
baseline and after 1 year. Furthermore, a tooth survival analysis was carried out. 37 
Results: After 13 years, 22 patients were available for tooth survival analysis showing 81.8% 38 
of test and 86.4% of control teeth still in situ. Based on the 15 patients still available for split-39 
mouth analysis, median CAL was 10.0 mm in test and 12.0 mm in control sites at baseline. 40 
After 1 year, both groups revealed significant CAL gains of 5.0 mm, followed by a new CAL 41 
loss of 1.0 mm in the following 12 years. There were no significant differences between test 42 
and control sites. 43 
Conclusion: Within the limits of this study, the data shows that most of the CAL gain 44 
following GTR can be maintained over 13 years. The additional use of APC had no positive 45 
influence on the long-term stability.  46 
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Clinical relevance 47 
Scientific rationale for the study 48 
To investigate the long-term outcomes 13 years after combined GTR/graft therapy with 49 
additional application of autogenous platelet concentrate (APC) in deep intrabony defects. 50 
 51 
Principal findings 52 
After 13 years, more than 80% of teeth were still in situ. Significant CAL gains were found 53 
after 1 and 13 years as compared to baseline irrespective of additional APC-application. 54 
However, a new attachment loss of 1 mm occurred between 1 and 13 years. 55 
 56 
Practical implications 57 
The clinical parameters after GTR/graft therapy can be maintained over a period of 13 years, 58 
while additional application of APC showed no additional benefit.  59 
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Introduction 60 
Guided tissue regeneration (GTR) is a widely accepted treatment concept for regenerative 61 
periodontal therapy by applying cell-occlusive membranes, which act as physical barriers 62 
preventing epithelial down-growth and maintaining a space for the slowly migrating cells of 63 
the periodontal ligament (Caffesse et al. 1988; Karring et al. 1993; Larsson et al. 2016). For 64 
the treatment of wide, non-containing intrabony defects, GTR is often combined with bone 65 
grafts, which stabilize the blood-clot and support the muco-periostal flap and the barrier 66 
membrane preventing a collapse into the defect (Cortellini & Tonetti 2015; Needleman et al. 67 
2006; Reynolds et al. 2014; Sculean et al. 2008b). 68 
However, there is still a high variability with regard to clinical outcomes after regenerative 69 
periodontal therapy due to several influence factors related to the individual patient, the 70 
defect or the surgical technique used (Cortellini & Tonetti 2000, 2015). Among patient-related 71 
factors, the innate wound healing potential of the individual patient is of vital importance for 72 
the healing outcomes (Kornman & Robe tson 2000) and is determined by the presence, 73 
amount and balance of growth factors crucial for periodontal wound healing, such as platelet-74 
derived growth factor (PDGF) or transforming growth factor-β (TGF-β) (Smith et al. 2015). 75 
Autogenous platelet concentrate (APC), often also referred to as platelet-rich plasma (PRP) 76 
(Marx, 2001), had been suggested as a natural, patient-own source of these relevant growth 77 
factors, as the α-granules of thrombocytes contain PDGF, TGF-β, and insulin-like growth 78 
factor (Bosshardt et al. 2015; Christgau et al. 2006a; Smith et al. 2015). APC had first been 79 
introduced in the field of oral and maxillofacial surgery in 1997 by Whitman et al. (Whitman et 80 
al. 1997), while Marx et al. had been the first to propose the use of PRP for the modulation of 81 
bone healing (Marx et al. 1998). Since then, several clinical studies have been published 82 
investigating the benefits of additional application of APC in regenerative periodontal therapy 83 
in combination either with GTR (Camargo et al. 2002; Cetinkaya et al. 2014), grafts (Demir et 84 
al. 2007; Hanna et al. 2004; Okuda et al. 2005; Yassibag-Berkman et al. 2007) or combined 85 
GTR/graft therapy (Camargo et al. 2005, 2009; Christgau et al. 2006b; Döri et al. 2007a, 86 
2007b, 2008; Moder et al. 2012). 87 
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In a prospective clinical split-mouth study from our group, the impact of additional application 88 
of APC on combined GTR/graft therapy with β-tricalcium phosphate (β-TCP) granules and a 89 
bio-resorbable, polylactic/polyglycolic acid copolymer (PLA/PGA) GTR membrane was 90 
investigated in deep intrabony defects (Christgau et al. 2006b). Apart from a tendency to less 91 
membrane exposures and an initially accelerated bone density gain during the first 6 months, 92 
no relevant effects on the early regeneration outcomes were found after 6 and 12 months 93 
(Christgau et al. 2006b). In contrast, after 7 years clinical results suggested even a possibly 94 
negative influence of APC showing less long-term stability of the clinical healing outcomes in 95 
test sites compared to the control sites without the additional application of APC (Moder et al. 96 
2012). To the best of our knowledge, there has been no study so far investigating the long-97 
term results of more than 7 years following combined GTR/graft therapy with additional 98 
application of APC. Furthermore, Wu et al. recently concluded in their systematic review on 99 
the long-term efficacy of periodontal regenerative therapy that there is still an urgent need for 100 
more long-term data (Wu et al. 2017). 101 
Consequently, the aim of this follow-up study was to evaluate the long-term outcomes 13 102 
years after combined GTR/graft therapy with and without additional application of APC. 103 
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Material and Methods 104 
Study design 105 
The present study is a 13-year follow-up of a controlled randomized prospective clinical split-106 
mouth study investigating the influence of additional application of autogenous platelet 107 
concentrate (APC) on the healing results in deep intrabony periodontal defects following 108 
guided tissue regeneration (GTR) combined with β-TCP (Christgau et al. 2006b). The study 109 
design followed the requirements outlined in the CONSORT 2010 statement (Moher et al. 110 
2010) and was approved by the ethics committee of the University of Regensburg in 111 
accordance with the 1964 Helsinki declaration and its later amendments or comparable 112 
ethical standards. After detailed description of the proposed treatments written informed 113 
consent was obtained from all individual participants included in the study. 114 
 115 
Patient selection 116 
The study originally included 25 systemically healthy patients recruited from the patient pool 117 
of the Department of Conservative Dentistry and Periodontology of the University Medical 118 
Center Regensburg. For inclusion in this study, all patients had to have one pair of contra-119 
lateral deep intrabony, interproximal periodontal defects with a probing pocket depth (PPD) 120 
of at least 6 mm and radiographic evidence of angular bone loss of at least 4 mm at baseline. 121 
None of the teeth showed furcation involvement. Full-mouth supra- and subgingival scaling 122 
and root planing as well as splinting of highly mobile teeth had to be successfully completed 123 
at least 4 to 6 weeks before surgery. None of the patients suffered from a systemic disease 124 
with a possibly negative influence on healing outcomes. 125 
 126 
Clinical therapeutic procedures 127 
The APC was prepared as described earlier in detail (Christgau et al. 2006a, 2006b). In brief, 128 
APCs were prepared at the Department of Transfusion Medicine of the University Medical 129 
Center Regensburg using an apheresis technique. For clinical application, 2.5 ml APC was 130 
reactivated with 0.5 ml of a sterile 10% calcium chloride solution. All surgical interventions 131 
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were performed by one experienced surgeon (MC) according to the principles of GTR 132 
therapy and have been described in detail earlier (Christgau et al. 2006b). Allocation of 133 
treatment sites to test and control groups was performed by means of a computer-generated 134 
randomization table created by a mathematician (KAH). 135 
Both defects in each patient were treated in the same session. Following sulcular incisions, 136 
buccal and oral muco-periosteal flaps were elevated. After debriding the defects thoroughly, 137 
test sites were treated as follows: root surfaces were conditioned with 24% EDTA gel 138 
(Prefgel; Straumann, Basel, Switzerland) for 2 min. After rinsing with sterile 0.9% sodium 139 
chloride solution, reactivated APC (Christgau et al. 2006a, 2006b) was applied to the root 140 
surfaces. Subsequently, the defects were filled with β-TCP granules (Ceros; Mathys, 141 
Bettlach, Switzerland), which had been soaked in APC, and covered with a bio-resorbable 142 
PLA/PGA membrane (Resolut XT; Gore Medical, Flagstaff, AZ, USA). The surgical sites 143 
were closed tension-free by coronally repositioned flaps. Control sites were treated 144 
accordingly without applying APC, whereby the β-TCP granules had been soaked with 145 
patient blood taken from the surgical site. Post-operative procedures were as described 146 
earlier (Christgau et al. 2006b). 147 
Within the first post-operative year, all patients were scheduled in a strict supportive 148 
periodontal therapy (SPT) program at the Department of Conservative Dentistry and 149 
Periodontology of the University Medical Center Regensburg with visits every 3 months. After 150 
that period, further participation in the SPT program was highly recommended but most of 151 
the patients returned to their referring dentists. The remaining patients were scheduled twice 152 
a year for SPT in the undergraduate program of the Department of Conservative Dentistry 153 
and Periodontology. 154 
 155 
Clinical examination 156 
Clinical examination was performed by two blinded examiners (FC; LT), who had been 157 
calibrated to the principal investigator (MC) in advance. The examiners were not involved in 158 
the treatments and not aware of the treatment modality used in the individual defects.  159 
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The clinical parameters were recorded immediately before as well as 1 and 13 years after 160 
periodontal surgery. Oral hygiene was measured by means of the full-mouth approximal 161 
plaque index (API) (Lange et al. 1977), gingival inflammation by means of the papillary 162 
bleeding index (PBI) (Saxer & Mühlemann, 1975).  163 
The subsequent clinical parameters were recorded for assessment of the healing results 164 
following regenerative therapy using a pressure-calibrated probe: gingival recession (REC) 165 
as the distance between cemento-enamel junction (CEJ) or the margin of a restauration to 166 
the gingival margin, probing pocket depth (PPD) as the distance from the gingival margin to 167 
the fundus of a periodontal pocket, and clinical attachment level (CAL) as the distance from 168 
the CEJ or the margin of a restauration to the fundus of a periodontal pocket. Furthermore, 169 
bleeding on probing (BOP) was measured. CAL change was determined to be the primary 170 
outcome variable. In addition, the vertical relative attachment gain (V-rAG) was calculated as 171 
the percentage of the CAL gain related to the BL depth of the osseous defect measured 172 
intra-operatively (Christgau et al. 2006b).  173 
 174 
Compliance 175 
For evaluation of the patients’ compliance, the regularity of participation in supportive 176 
periodontal therapy (SPT) was calculated based on the dental chart of each individual 177 
patient. A patient who attended SPT at the Department of Conservative Dentistry and 178 
Periodontology of the University Medical Center Regensburg at least once per year was 179 
classified to have ‘regular SPT’. Patients who failed no more than one year during the whole 180 
13-year-period were considered to have ‘irregular SPT’. Patients failing more often were 181 
classified to have ‘no SPT’ at the University Medical Center. 182 
 183 
Data analysis 184 
The single patient was regarded to be the statistical unit in this study. As discussed earlier 185 
(Christgau et al. 1997), clinical measurements were reported as median values (with 186 
25%/75% percentiles) and were statistically evaluated using a non-parametric procedure. 187 
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Considering the paired nature of the split-mouth data, the Wilcoxon-Signed-rank test was 188 
applied on a significance level of α=0.05 using SPSS for Windows, version 23 (SPSS Inc., 189 
Chicago, IL, USA) (Woolson & Clarke, 2002).  190 
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Results 191 
All initially recruited 25 patients received the intended treatment and completed the 1-year 192 
observation period (baseline to 12 months) (Christgau et al. 2006b). After 13 years, 3 193 
patients were not available anymore. 21 of the remaining 22 patients could be scheduled for 194 
clinical examination, while the other patient was only available for an oral interview via 195 
telephone. 196 
Due to tooth extractions by the referring dentists for prosthodontic reasons, only 15 patients 197 
were suitable for pair-wise split-mouth analysis after 13 years (Figure 1). A tooth survival 198 
analysis could be performed in 22 patients. Figure 2 exemplarily shows the radiographic 199 
healing in a control site at baseline as well as 1 and 13 years following regenerative therapy. 200 
 201 
Compliance with SPT 202 
The calculation of the SPT frequencies was carried out based on the dental charts of the 22 203 
patients who were available for tooth survival analysis. 23% of the patients had participated 204 
regularly in SPT, 18% had participated irregularly, and 59% received no SPT at the 205 
University Medical Center. 206 
 207 
Tooth survival analysis 208 
Tooth survival was analyzed in 22 patients. After 13 years, 7 teeth in 6 patients had been 209 
extracted by the referring dentists due to prosthodontic reasons: 4 teeth in the test group and 210 
3 teeth in the control group. Accordingly, 81.8% and 86.4% of the teeth were still in situ in the 211 
test or control group, respectively. No association of tooth loss could be found with regard to 212 
tooth type while there was a tendency for more tooth loss in initially deeper defects (6 out of 213 
7 tooth losses occurred in teeth with CAL of 12.0 mm or more at baseline; Table 1). 214 
Furthermore, poor compliance with the participation in SPT seemed to have an impact on 215 
tooth loss as well: it occurred in 3 patients with no SPT, in 2 patients with irregular SPT, and 216 
only in 1 patient with regular SPT at the University Medical Center. 217 
 218 
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Clinical parameters 219 
For split-mouth analysis, the clinical data of 15 patients was available. The median full-mouth 220 
API increased from 10% at baseline to 12% after 1 year and 25% after 13 years, while the 221 
median full-mouth PBI declined from 14% at baseline to 10% after 1 year and 4% after 13 222 
years. These differences were not statistically significantly different. The median PBI at the 223 
surgical sites was 1.0 at baseline in both, test and control sites, decreased to 0.0 after 1 224 
year, and remained stable after 13 years. The median BOP was positive (bleeding) in both 225 
groups at baseline, negative (no bleeding) after 1 year and positive again after 13 years. 226 
Both groups showed a median baseline PPD of 10.0 mm, which decreased by 6.0 mm (both 227 
groups) to 3.0 mm (test) or 4.0 mm (control), respectively, after 1 year. After 13 years, 228 
median PPD increased again by 1.0 mm to 5.0 mm (both groups). The median REC started 229 
at baseline at 1.0 mm (test) or 2.0 mm (control) and increased to 3.0 mm (both) after 1 year, 230 
declining again in test group to 2.0 mm while remaining stable in the control group after 13 231 
years. The median CAL at baseline was found to be 10.0 mm in test sites and 12.0 mm in 232 
control sites and improved by 5.0 mm to 6.0 mm in both groups after 1 year. After 13 years, 233 
the median CAL increased again by 1.0 mm to 7.0 mm in both groups. The vertical relative 234 
attachment gain after 1 year was found to be 75% in the test and 76.9% in the control group 235 
and decreased to 50% in the test and 66.7% in the control group after 13 years. No 236 
significant differences between test and control sites were found. The results of the clinical 237 
examination are summarized in Tables 2 and 3. Additionally, Table 4 shows the frequency 238 
distribution of sites with PPD ≤ 3 mm, 4-5 mm as well as ≥ 6 mm for all test and control sites 239 
at baseline as well as after 1 and 13 years.  240 
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Discussion 241 
The present study investigated the long-term healing outcomes 13 years after combined 242 
GTR/graft therapy with or without additional application of autogenous platelet concentrate. 243 
In general, studies reporting on long-term outcomes after regenerative periodontal therapies 244 
are scarce (Wu et al. 2017). To date, there are only five prospective randomized clinical trials 245 
on GTR or combined GTR/graft therapy in intrabony defects with follow-up for 10 years 246 
(Nickles et al. 2009; Nygaard-Østby et al. 2010; Pretzl et al. 2008, 2009; Sculean et al. 247 
2008a) and only one very recent study on GTR with a longer observation period (i.e. 20 248 
years) than in the present study (Cortellini et al. 2017). Furthermore, this is the first study 249 
investigating the impact of APC on the long-term clinical healing outcomes after combined 250 
GTR/graft therapy. 251 
 252 
Clinical parameters 253 
A general drawback of this kind of long-term studies is the fact that usually only a part of the 254 
initial patient population is still available. Accordingly, in the present study only 15 patients 255 
were still available for split-mouth analysis after 13 years, while in the original study 25 256 
patients had been included, contributing test and control defects for split-mouth analysis 257 
each. Therefore, a reduced statistical power of the long-term data must be accepted and, 258 
consequently, the results have to be interpreted with caution. While in the original study on 259 
25 patients test and control defects both showed a median baseline CAL of 10.0 mm 260 
(Christgau et al. 2006b), in this 13-year follow-up the baseline CAL was 10.0 mm in test and 261 
12.0 mm in control sites. This can be explained by the selection of the 15 patients, who were 262 
still available for split-mouth analysis after 13 years. However, this difference in baseline CAL 263 
was not statistically significant. 264 
In the present study, the median CAL gain 1 year after periodontal surgery measured 5.0 mm 265 
in both groups. These results were in the upper range compared to those of previous studies 266 
on GTR therapy with bio-resorbable membranes in intrabony defects (Murphy & Gunsolley 267 
2003), where at best a mean CAL gain of 4.60 mm was reported 1 year after GTR using 268 
Page 18 of 37
Journal of Clinical Periodontology - PROOF
Journal of Clinical Periodontology - PROOF
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
13/27 
PLA/PGA membranes (Cortellini et al. 1996). The better outcomes in our study may be 269 
explained by the combination with graft material. 270 
Studies reporting on long-term results after GTR or combined GTR/graft therapy with bio-271 
resorbable membranes in intrabony defects found mean CAL gains in a range between 2.4 272 
to 3.8 mm 10 years postoperatively (Nickles et al. 2009; Nygaard-Østby et al. 2010; Pretzl et 273 
al. 2008, 2009; Sculean et al. 2008a). Nygaard-Østby et al. observed a mean CAL gain of 274 
3.8 mm 10 years after GTR therapy with bio-resorbable polylactide (PLA) membranes 275 
combined with autogenous bone graft (Nygaard-Østby et al. 2010). Our 13-year results 276 
revealed median CAL gains of 3.0 mm in the test and 5.0 mm in the control group, which 277 
were not statistically significantly different. Although these CAL gains are similar or slightly 278 
better as compared to the afore-mentioned long-term studies, we observed a new median 279 
CAL loss of 1.0 mm in both groups between the 1-year and the 13-year follow-up. This is 280 
also reflected in the frequency distribution of sites with PPD ≤ 3 mm, 4-5 mm as well as ≥ 6 281 
mm at the 3 examination time points: while after 1 year all sites showed PPD of maximum 5 282 
mm, after 13 years some sites worsened again (7 and 4 sites with PPD ≥ 6 mm for test and 283 
control group, respectively). These results are in line with the literature, where CAL changes 284 
ranged from a mean CAL loss of 1.62 mm between 1 and 10 years postoperatively (Pretzl et 285 
al. 2009) to a mean CAL gain of 1.2 mm between 9 months and 10 years after surgery 286 
(Nygaard-Østby et al. 2010). This additional CAL gain in the latter study was explained by a 287 
still not complete tissue maturation after 9 months (Nygaard-Østby et al. 2010). In the study 288 
with the longest follow-up period in the literature, Cortellini et al. found mean CAL losses of 289 
0.1 mm or 0.5 mm dependent on the respective surgical technique (modified papilla 290 
preservation technique or conventional access flap, respectively) between 1 and 20 years 291 
after GTR therapy using expanded polytetrafluoroethylene (ePTFE) membranes (Cortellini et 292 
al. 2017).  293 
 294 
Tooth loss and compliance 295 
Hujoel et al. suggested to use true end points (e.g. tooth loss) in addition to surrogate 296 
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parameters (e.g. CAL changes) for evaluation of distinct periodontal treatment approaches 297 
(Hujoel et al. 2000). In this clinical trial, 13 years after periodontal surgery 81.8% and 86.4% 298 
of the teeth were still in situ in the test or control group, respectively. Consequently, 7 teeth 299 
(test: 4; control: 3) in 6 patients were lost during the study period. However, the decisions for 300 
tooth retention or extraction were made alio loco by the respective referring dentists. 301 
According to the patients’ self-report, the tooth extractions were due to prosthodontic reasons 302 
(mostly in the context of more complex prosthetic rehabilitations) and thus may not be 303 
considered as periodontal complications. 304 
It is well-known that regular participation in supportive periodontal therapy (SPT) is crucial for 305 
long-term success of periodontal treatment (Axelsson & Lindhe 1978; Axelsson et al. 2004). 306 
Cortellini & Tonetti found significantly more new attachment loss and tooth loss in cases 307 
without regular SPT in a cumulative long-term analysis up to 16 years following GTR 308 
(Cortellini & Tonetti, 2004). In the present study, all patients had to attend SPT every 3 309 
months during the first year postoperatively. However, during the following 12 years, only 310 
23% of the patients further participated in the SPT program at the University Medical Center 311 
on a regular basis (i.e. at least once per year) and 18% received SPT irregularly (i.e. 312 
maximum one year without SPT during the entire study period). In contrast, 59% of the 313 
patients did not further attend SPT at the University Medical Center during this period (i.e. 314 
two or more years without attendance). This may be reflected in the tooth survival analysis, 315 
where 5 out of the 6 patients with tooth loss showed no or irregular SPT attendance at the 316 
University Medical Center. However, due to the geographical context and the wide 317 
catchment area of the University Medical Center Regensburg many patients had to accept 318 
long ways accompanied by additional costs to reach the University Medical Center and most 319 
of them preferred to attend their local dentists after the 1-year follow-up. Return of the 320 
patients to their referring dentists does not necessarily mean insufficient professional 321 
maintenance. However, the quality of the maintenance could not be controlled by the 322 
investigators. Having this in mind, it is noteworthy that the oral hygiene parameters remained 323 
quite stable over the 13-year period with a slightly increasing full-mouth API (10% at 324 
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baseline, 12% after 1 year, 25% after 13 years) and even marginally decreasing full-mouth 325 
PBI (14% at baseline, 10% after 1 year, 4% after 13 years). Furthermore, it has to be 326 
emphasized that both, test and control sites, suffered equally from the low participation in 327 
SPT at the University Medical Center because due to the split-mouth design every patient 328 
served as his or her own control (Hujoel & Moulton 1988; Koch & Paquette 1997). 329 
 330 
Impact of additional application of APC 331 
As the aim of the original split-mouth study was to investigate the effects of APC on clinical 332 
healing outcomes after combined GTR/graft therapy, all influence factors were kept constant 333 
besides the additional application of APC. Therefore, a negative control group (i.e. access 334 
flap surgery) had not been included in this split-mouth study. 335 
In the present study, no benefits of additional application of APC were found on long-term 336 
clinical healing outcomes following combined GTR/graft therapy. However, these results 337 
should be interpreted with caution as only 15 out of the original 25 were still available for 338 
split-mouth analysis after 13 years, wherefore a reduced statistical power must be accepted. 339 
Nevertheless, the results of this study are in accordance with some recent systematic 340 
reviews concluding that platelet concentrates may reveal a positive adjunctive effect on 341 
periodontal regenerative therapy outcomes in intrabony defects when combined with graft 342 
materials alone, but not in combination with GTR or combined GTR/graft therapy (Del Fabbro 343 
et al. 2011; Hou et al. 2016; Panda et al. 2016; Roselló-Camps et al. 2015). It was suggested 344 
that the proven efficacy of GTR could mask additional effects of platelet concentrates. When 345 
using graft materials without membranes, the dense fibrin network formed after platelet 346 
activation may act as a barrier and prevent epithelial migration into the defect, explaining the 347 
superior results in these cases (Del Fabbro et al. 2011; Panda et al. 2016). 348 
In the 7-year follow-up of our study, it was found that the test sites exhibited worse clinical 349 
healing outcomes than the control sites in terms of a statistically significant greater increase 350 
in PPD and CAL loss from 1 to 7 years (Moder et al. 2012). After 13 years, we still found less 351 
median CAL gain between baseline and 13 years for test (3.0 mm) than control sites (5.0 352 
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mm), which was however not found to be statistically significant anymore. Likewise, the 353 
frequency distribution of sites with PPD ≤ 3 mm, 4-5 mm as well as ≥ 6 mm showed slightly 354 
more worsening of test sites after 13 years as compared to control sites. Although the 355 
baseline characteristics of test and control defects exhibited no statistically significant 356 
differences, there was a tendency for worse median CAL at baseline in control (12.0 mm) 357 
than in test defects (10.0 mm). This may explain the trend for better performance of control 358 
than test defects because it is well-known that defects with greater defect depth at baseline 359 
may have a better potential for periodontal regeneration than more shallow defects (Kornman 360 
& Robertson 2000).  361 
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Conclusions 362 
• Most of the CAL gain found 1 year after combined GTR/graft therapy could be 363 
maintained over a period of 13 years, although there was some new CAL loss 364 
between 1 and 13 years. 365 
• Within the limitations of this 13-year study, the application of APC showed no 366 
statistically significant benefits on the long-term clinical healing outcomes. This is in 367 
line with the 1-year results of the original study. 368 
 369 
 370 
 371 
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Tables 554 
Table 1. Frequency distribution of tooth loss in test and control sites according to tooth type 555 
and clinical attachment level (CAL) at baseline. 556 
  test  control 
     
Tooth type    
Incisors, canines  2  1 
Premolars  2  0 
Molars  0  2 
Total  4  3 
 
 
    
CAL at baseline     
10 mm  1  0 
11 mm  0  0 
12 mm  0  1 
13 mm  3  1 
14 mm  0  1 
Total  4  3 
 557 
n: number of lost teeth.  558 
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Table 2. Split mouth analysis: papillary bleeding index (PBI), bleeding on probing (BOP), 559 
gingival recession (REC), probing pocket depth (PPD) and clinical attachment level (CAL) at 560 
the surgical sites at baseline as well as after 1 and 13 years (median, 25%/75% percentiles).  561 
 562 
 test sites (n=15)  control sites (n=15) 
            
 PBI BOP* REC 
[mm] 
PPD 
[mm] 
CAL 
[mm] 
 PBI BOP* REC 
[mm] 
PPD 
[mm] 
CAL 
[mm] 
            
baseline            
   median 1.02 1.01,3 1.01,2 10.01,2 10.01,2  1.0 1.0 2.01,2 10.01,2 12.01,2 
   25% 0.0 0.0 0.0 9.0 9.0  0.0 0.0 0.0 9.0 10.0 
   75% 1.0 1.0 3.0 10.0 12.0  2.0 1.0 3.0 10.0 13.0 
            
1 year            
   median 0.0 0.01 3.01 3.01,3 6.01  0.0 0.03 3.01 4.01 6.01 
   25% 0.0 0.0 1.0 3.0 4.0  0.0 0.0 1.0 3.0 5.0 
   75% 1.0 0.0 5.0 4.0 7.0  1.0 1.0 4.0 5.0 7.0 
            
13 years            
   median 0.02 1.03 2.02 5.02,3 7.02  0.0 1.03 3.02 5.02 7.02 
   25% 0.0 0.0 2.0 3.0 5.0  0.0 1.0 2.0 3.0 6.0 
   75% 0.0 1.0 5.0 6.0 10.0  2.0 1.0 5.0 6.0 8.0 
            
n: number of split-mouth defects; 563 
*: 0=negative, 1=positive; 564 
+: statistically significant difference between test and control (p≤0.05); 565 
1: statistically significant difference between baseline and 1-year (p≤0.05); 566 
2: statistically significant difference between baseline and 13-years (p≤0.05); 567 
3: statistically significant difference between 1-year and 13-years (p≤0.05).  568 
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Table 3. Split mouth analysis: changes in gingival recession (REC), probing pocket depth 569 
(PPD), clinical attachment level (CAL) and vertical relative attachment gain (V-rAG) at the 570 
surgical sites after 1 and 13 years (median, 25%/75% percentiles). 571 
 572 
  test sites (n=15)  control sites (n=15) 
           
  ∆REC 
[mm] 
∆PPD 
[mm] 
∆CAL 
[mm] 
V-rAG 
[%] 
 ∆REC 
[mm] 
∆PPD 
[mm] 
∆CAL 
[mm] 
V-rAG 
[%] 
           
baseline – 1 year           
   median  -1.02 6.01,2 5.02 752  -1.0 6.02 5.02 76.92 
   25%  -2.0 5.0 4.0 66.7  -1.0 5.0 4.0 55.6 
   75%  0.0 7.0 5.0 83.3  0.0 6.0 7.0 87.5 
           
baseline – 13 years           
   median  -2.0 4.01,3 3.03 503  -1.03 5.03 5.03 66.73 
   25%  -3.0 3.0 2.0 30  -2.0 4.0 3.0 33.3 
   75%  0.0 6.0 5.0 100  0.0 6.0 6.0 75 
           
1 year – 13 years           
   median  0.02 -1.02,3 -1.02,3 -202,3  0.03 -1.02,3 -1.02,3 -12.52,3 
   25%  -2.0 -3.0 -2.0 -33.3  -1.0 -2.0 -2.0 -25 
   75%  1.0 0.0 1.0 20  1.0 0.0 1.0 10 
           
n: number of split-mouth defects; 573 
+: statistically significant difference between test and control (p≤0.05); 574 
1: statistically significant difference between (BL – 1 year) and (BL – 13 years) (p≤0.05); 575 
2: statistically significant difference between (BL – 1 year) and (1 year – 13 years) (p≤0.05); 576 
3: statistically significant difference between (BL – 13 year) and (1 year – 13 years) (p≤0.05). 577 
  578 
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Table 4. Split mouth analysis: Frequency distribution of PPD ≤ 3 mm, 4-5 mm as well as ≥ 6 579 
mm at the surgical sites at baseline as well as after 1 and 13 years.  580 
 581 
  test sites (n=15)  control sites (n=15) 
     
  ≤ 3 mm 4-5 mm ≥ 6 mm  ≤ 3 mm 4-5 mm ≥ 6 mm 
         
baseline  - - 15  - - 15 
         
1 year  8 7 -  6 9 - 
         
13 years  4 4 7  4 7 4 
         
n: number of split-mouth defects.  582 
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Figure Legends  583 
 584 
Figure 1: Flowchart of the study outline. 585 
 586 
Figure 2: Radiographic healing in a control site at baseline as well as 1 and 13 years 587 
after combined GTR/graft treatment without additional application of APC. 588 
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Radiographic healing in a control site at baseline as well as 1 and 13 years after combined GTR/graft 
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CONSORT 2010 checklist of information to include when reporting a randomised trial* 
 
Section/Topic 
Item 
No Checklist item 
Reported 
on page No 
Title and abstract 
 1a Identification as a randomised trial in the title 1 
1b Structured summary of trial design, methods, results, and conclusions (for specific guidance see CONSORT for abstracts) 2 
Introduction 
Background and 
objectives 
2a Scientific background and explanation of rationale 4-5 
2b Specific objectives or hypotheses 5 
Methods 
Trial design 3a Description of trial design (such as parallel, factorial) including allocation ratio 6-7 
3b Important changes to methods after trial commencement (such as eligibility criteria), with reasons n/a 
Participants 4a Eligibility criteria for participants 6 
4b Settings and locations where the data were collected 6-8 
Interventions 5 The interventions for each group with sufficient details to allow replication, including how and when they were 
actually administered 
6-7 
Outcomes 6a Completely defined pre-specified primary and secondary outcome measures, including how and when they 
were assessed 
7-8 
6b Any changes to trial outcomes after the trial commenced, with reasons n/a 
Sample size 7a How sample size was determined 8-9 
7b When applicable, explanation of any interim analyses and stopping guidelines n/a 
Randomisation:    
 Sequence 
generation 
8a Method used to generate the random allocation sequence 7 
8b Type of randomisation; details of any restriction (such as blocking and block size) 7 
 Allocation 
concealment 
mechanism 
9 Mechanism used to implement the random allocation sequence (such as sequentially numbered containers), 
describing any steps taken to conceal the sequence until interventions were assigned 
7 
 Implementation 10 Who generated the random allocation sequence, who enrolled participants, and who assigned participants to 
interventions 
6-7 
Blinding 11a If done, who was blinded after assignment to interventions (for example, participants, care providers, those 7 
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assessing outcomes) and how 
11b If relevant, description of the similarity of interventions n/a 
Statistical methods 12a Statistical methods used to compare groups for primary and secondary outcomes 8-9 
12b Methods for additional analyses, such as subgroup analyses and adjusted analyses n/a 
Results 
Participant flow (a 
diagram is strongly 
recommended) 
13a For each group, the numbers of participants who were randomly assigned, received intended treatment, and 
were analysed for the primary outcome 
10 
13b For each group, losses and exclusions after randomisation, together with reasons 10 
Recruitment 14a Dates defining the periods of recruitment and follow-up 10 
14b Why the trial ended or was stopped n/a 
Baseline data 15 A table showing baseline demographic and clinical characteristics for each group 23-26 
Numbers analysed 16 For each group, number of participants (denominator) included in each analysis and whether the analysis was 
by original assigned groups 
10 
Outcomes and 
estimation 
17a For each primary and secondary outcome, results for each group, and the estimated effect size and its 
precision (such as 95% confidence interval) 
10-11 
17b For binary outcomes, presentation of both absolute and relative effect sizes is recommended n/a 
Ancillary analyses 18 Results of any other analyses performed, including subgroup analyses and adjusted analyses, distinguishing 
pre-specified from exploratory 
10-11 
Harms 19 All important harms or unintended effects in each group (for specific guidance see CONSORT for harms) n/a 
Discussion 
Limitations 20 Trial limitations, addressing sources of potential bias, imprecision, and, if relevant, multiplicity of analyses 12-16 
Generalisability 21 Generalisability (external validity, applicability) of the trial findings 12-16 
Interpretation 22 Interpretation consistent with results, balancing benefits and harms, and considering other relevant evidence 12-16 
Other information  
Registration 23 Registration number and name of trial registry n/a 
Protocol 24 Where the full trial protocol can be accessed, if available n/a 
Funding 25 Sources of funding and other support (such as supply of drugs), role of funders 1, 17 
 
*We strongly recommend reading this statement in conjunction with the CONSORT 2010 Explanation and Elaboration for important clarifications on all the items. If relevant, we also 
recommend reading CONSORT extensions for cluster randomised trials, non-inferiority and equivalence trials, non-pharmacological treatments, herbal interventions, and pragmatic trials. 
Additional extensions are forthcoming: for those and for up to date references relevant to this checklist, see www.consort-statement.org. 
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